本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300436 证券简称：广生堂 公告编号：2025065 福建广生堂药业股份有限公司 关于 2025 年第二次临时股东大会决议的公告 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 1、现场会议召开时间：2025 年 9 月 17 日（星期三）14:30 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 17 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 17 日 9:15—15:00。 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室。 （三）会议召集人：公司董事会 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会议召 ...

Group 1 - The "Second Golden Kylin Best Investment Advisor Selection" event is currently ongoing, with over 3,000 professional investment advisors participating in simulated trading competitions [1][4] - The event aims to provide a platform for investment advisors to showcase their capabilities and enhance communication with the public, thereby promoting the healthy development of China's wealth management industry [1] Group 2 - The top 10 stocks by purchase frequency on September 17 include 华胜天成 (Huasheng Tiancai), 协创数据 (Xiechuang Data), and 绿的谐波 (Green Harmonics) [1] - The top 10 stocks by purchase amount on September 17 include 胜宏科技 (Shenghong Technology), 双环传动 (Shuanghuan Transmission), and 汉宇集团 (Hanyu Group) [2] - The data for the top purchased stocks and ETFs is based on the frequency and amount of purchases made by all participating advisors [3]

Market Overview - The Shanghai Composite Index rose by 0.37% on September 17, with 20 industries experiencing gains, led by the power equipment and automotive sectors, which increased by 2.55% and 2.05% respectively [1] - Conversely, the agriculture, forestry, animal husbandry, and fishery sectors, along with retail, saw declines of 1.02% and 0.98% respectively [1] - The pharmaceutical and biotechnology sector fell by 0.23% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 38.306 billion yuan, with five industries seeing net inflows [1] - The power equipment sector led the net inflow with 1.835 billion yuan, followed by the automotive sector with 1.142 billion yuan [1] - The non-bank financial sector experienced the largest net outflow, totaling 5.229 billion yuan, followed by the computer sector with a net outflow of 4.455 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 3.977 billion yuan, with 474 stocks in the sector; 135 stocks rose while 327 fell [2] - The top net inflow stocks included WuXi AppTec with 352 million yuan, followed by Hengrui Medicine and Boteng Co., with inflows of 312 million yuan and 55.426 million yuan respectively [2] - Nine stocks in the sector experienced net outflows exceeding 100 million yuan, with the largest outflows from Guangsheng Tang, Sino Medical, and Ganli Pharmaceutical, amounting to 253 million yuan, 164 million yuan, and 140 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - WuXi AppTec: +2.09%, turnover rate 2.01%, net inflow 351.585 million yuan [2] - Hengrui Medicine: +1.42%, turnover rate 0.92%, net inflow 312.024 million yuan [2] - Boteng Co.: -0.93%, turnover rate 6.09%, net inflow 55.426 million yuan [2] Top Losers in Pharmaceutical Sector - Guangsheng Tang: -4.40%, turnover rate 9.74%, net outflow -252.737 million yuan [3] - Sino Medical: -1.74%, turnover rate 5.85%, net outflow -164.152 million yuan [3] - Ganli Pharmaceutical: -1.74%, turnover rate 2.88%, net outflow -139.861 million yuan [3]

Group 1 - The "Second Golden Unicorn Best Investment Advisor Selection" event is currently ongoing, with over 3,000 professional investment advisors participating in simulated portfolio competitions [1] - The event aims to provide a platform for investment advisors to showcase their capabilities, expand services, and enhance skills, thereby promoting the healthy development of China's wealth management industry [1] Group 2 - The top ten stocks by buy volume on September 16 include: Huasheng Tiancheng, Xiechuang Data, and Green Harmony, among others [2] - The top ten stocks by buy amount on September 16 include: Shenghong Technology, Shuanghuan Transmission, and Hanyu Group, among others [3] - The data for the top buy stocks/ETFs is based on the frequency of purchases by all participating advisors, while the buy amount data reflects the top ten stocks/ETFs by total investment amount [4]

Group 1 - The core viewpoint of the news is that Guangshengtang's stock price has dropped by 5% to 114.57 CNY per share, with a trading volume of 9.67 billion CNY and a turnover rate of 6.00%, resulting in a total market capitalization of 182.47 billion CNY [1] - Guangshengtang Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its main business revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and went public on April 22, 2015, located in Fuzhou, Fujian Province [1] Group 2 - Among the top ten circulating shareholders of Guangshengtang, a fund under China Europe Fund has increased its holdings by 393,100 shares, bringing its total to 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has a current scale of 15.638 billion CNY and has achieved a year-to-date return of 32.89% [2] - The fund manager, Ge Lan, has a tenure of 10 years and 234 days, with the best fund return during this period being 128.39% [3]

Group 1 - The core viewpoint of the news is that Guangshengtang has seen a significant increase in its stock price, rising by 5.01% to reach 119.76 yuan per share, with a trading volume of 1.188 billion yuan and a turnover rate of 7.52%, resulting in a total market capitalization of 19.074 billion yuan [1] - Guangshengtang Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its main business revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and was listed on April 22, 2015, located in Fuzhou, Fujian Province [1] Group 2 - Among the top ten circulating shareholders of Guangshengtang, a fund under China Europe Fund has increased its holdings by 393,100 shares, bringing its total to 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed Fund A (003095) has achieved a year-to-date return of 31.02% and a one-year return of 47.65%, ranking 2473 out of 8174 and 3246 out of 7981 respectively [2] - The fund manager, Ge Lan, has a tenure of 10 years and 230 days, with the fund's total asset size at 39.908 billion yuan and a best return of 128.86% during her tenure [3]

Group 1 - The chemical pharmaceutical sector increased by 0.78% on September 12, with Yuan Dong Biological leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] - Notable gainers in the chemical pharmaceutical sector included Yuan Dong Biological, which rose by 11.33% to a closing price of 58.88, and Nuo Cheng Jian Hua, which increased by 11.14% to 29.62 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 628 million yuan from institutional investors, while retail investors experienced a net outflow of 776 million yuan [2][3] - Major stocks with significant net inflows included Guang Sheng Tang with 264 million yuan and An Li Kang with 130 million yuan [3] - Conversely, stocks like Tai En Kang and Xin Ju Wei faced declines of 3.89% and 2.41%, respectively, indicating mixed performance within the sector [2]

Group 1 - The core viewpoint of the news is that Guangshentang's stock has shown significant volatility, with a year-to-date increase of 256.60% and a recent decline of 30.34% over the past 20 days [1][2] - As of June 30, 2025, Guangshentang reported a revenue of 2.09 billion yuan, a year-on-year decrease of 4.27%, and a net profit loss of 666.88 million yuan, down 85.05% compared to the previous year [2] - The company has a market capitalization of 18.55 billion yuan and has seen a net outflow of 57.38 million yuan in major funds recently [1] Group 2 - Guangshentang's main business involves the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] - The company has been listed on the stock market since April 22, 2015, and has made a total cash distribution of 84.65 million yuan since its IPO, with no distributions in the last three years [3] - As of June 30, 2025, the number of shareholders increased by 44.75% to 20,300, while the average circulating shares per person decreased by 30.91% to 6,745 shares [2][3]

Group 1 - Jimin Health has experienced a significant increase, with 6 consecutive trading limits reached in 12 days [1] - Shutai Shen has risen over 7%, indicating strong market interest [1] - Hot景生物 has seen an increase of over 5%, reflecting positive investor sentiment [1] Group 2 - Other companies such as Meidi Xi, Guangsheng Tang, and Borui Pharmaceutical have also shown upward trends in their stock prices [1]

Group 1 - The core point of the article highlights the recent decline in Guangshentang's stock price, which fell by 5.03% to 144.31 CNY per share, with a trading volume of 1.535 billion CNY and a turnover rate of 7.51%, resulting in a total market capitalization of 22.984 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is based in Fuzhou, Fujian Province, and specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), increased its holdings by 393,100 shares in the second quarter, now holding 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed A fund has a current scale of 15.638 billion CNY and has achieved a year-to-date return of 31.12%, ranking 1981 out of 8194 in its category, with a one-year return of 46.49%, ranking 2733 out of 7962 [2]